${\small \mathsf{CLINICAL}} \ {\small \mathsf{REPORT}} \ {\small \mathsf{Guidance}} \ {\small \mathsf{for}} \ {\small \mathsf{the}} \ {\small \mathsf{Clinician}} \ {\small \mathsf{in}} \ {\small \mathsf{Rendering}} \ {\small \mathsf{Pediatric}} \ {\small \mathsf{Care}}$

American Academy of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN"

Evaluation for Bleeding Disorders in Suspected Child Abuse

James Anderst, MD, MSCI, FAAP,^a Shannon L. Carpenter, MD, MS, FAAP,^b Thomas C. Abshire, MD,^c Emily Killough, MD, FAAP,^a AAP SECTION ON HEMATOLOGY/ONCOLOGY, THE AMERICAN SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY, THE AAP COUNCIL ON CHILD ABUSE AND NEGLECT

Bruising or bleeding in a child can raise the concern for child abuse. Assessing whether the findings are the result of trauma and/or whether the child has a bleeding disorder is critical. Many bleeding disorders are rare, and not every child with bruising/bleeding that may raise a concern for abuse requires an evaluation for bleeding disorders. However, in some instances, bleeding disorders can present in a manner similar to child abuse. Bleeding disorders cannot be ruled out solely on the basis of patient and family history, no matter how extensive. The history and clinical evaluation can be used to determine the necessity of an evaluation for a possible bleeding disorder, and prevalence and known clinical presentations of individual bleeding disorders can be used to guide the extent of laboratory testing. This clinical report provides guidance to pediatricians and other clinicians regarding the evaluation for bleeding disorders when child abuse is suspected.

STATEMENT OF PROBLEM

Significant variability exists in the evaluation of suspected child abuse, including the evaluation for bleeding disorders.^{1–4} The purpose of this clinical report is to reduce variability by providing guidance to pediatricians and other clinicians regarding the evaluation for bleeding disorders when suspicious bruising or intracranial hemorrhage (ICH) is present (Fig 1).

NEW INFORMATION

On the basis of recent data, this clinical report provides updated recommendations for:

- 1. Evaluating bleeding disorders in suspected child abuse (Fig 1);
- 2. Identifying bruising that is suspicious for child abuse;

abstract

^a Division of Child Adversity and Resilience, Children's Mercy Hospital, Department of Pediatrics, University of Missouri Kansas City School of Medicine, Kansas City, Missouri; ^b Division of Hematology/Oncology/BMT, Children's Mercy Hospital, Department of Pediatrics, University of Missouri Kansas City School of Medicine, Kansas City, Missouri; and ^oSenior Investigator Emeritus, Versiti Blood Research Institute, Department of Pediatrics, Medicine, and the CT SI of Southeast Wisconsin, Emeritus, Medical College of Wisconsin, Milwaukee, Wisconsin

Drs Anderst and Killough created the initial and subsequent drafts of the document; Drs Carpenter and Abshire provided editing to the initial and subsequent drafts; and all authors conceptualized and outlined the manuscript.

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.

Clinical reports from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal and external reviewers. However, clinical reports from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent.

The guidance in this report does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

All clinical reports from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

DOI: https://doi.org/10.1542/peds.2022-059276

To cite: Anderst J, Carpenter SL, Abshire TC; AAP Section on Hematology/Oncology, American Society of Pediatric Hematology/Oncology, AAP Council on Child Abuse And Neglect. Evaluation for Bleeding Disorders in Suspected Child Abuse. *Pediatrics*. 2022;150(4):e2022059276

PEDIATRICS Volume 150, number 4, October 2022:e2022059276

Downloaded from http://publications.aap.org/pediatrics/article-pdf/150/4/e2022059276/1374648/peds_2022059276.pdf by Poria Medical Center user

FROM THE AMERICAN ACADEMY OF PEDIATRICS

- Identifying bruising that may commonly be seen in children with congenital bleeding disorders;
- 4. Testing for factor XIII deficiency in children with ICH;
- 5. Testing for deficiencies of factor VIII and factor IX in children with subdural hemorrhage (SDH) on the basis of history of trauma;
- 6. Testing for deficiencies of factor VIII and factor IX in females; and
- 7. The utility of whole blood-clotting assays for testing for bleeding disorders.

INTRODUCTION

Children often present for medical care with bleeding or bruising that can raise a concern for child abuse. Most commonly, this occurs with cutaneous bruises and ICH, particularly SDH, but other presentations, such as hematemesis,⁵ hematochezia,⁶ and oronasal bleeding can be caused by child abuse and/or bleeding disorders.⁷⁻⁹ When bleeding or bruising is suspicious for child abuse, careful consideration of medical and nonmedical causes is important. Mistaken diagnosis, whether an inappropriate finding of abuse, a missed case of abuse, or overlooking of a medical cause, can cause harm to the child and his or her family.^{10–13} Infants, in particular, are at high risk of abusive bruising/bleeding; however, bleeding disorders may also present in infancy in a similar manner to abusive bruising or bleeding.^{13–18}

The patient's medical and family history of bleeding/bruising, no matter how thorough, cannot completely eliminate a bleeding disorder as the cause of a patient's findings.^{19,20} For instance, male infants who have had a circumcision with no significant bleeding issues may still have a bleeding disorder.²¹ As such, laboratory evaluations are often necessary to detect bleeding disorders. However, the presence of a bleeding disorder does not rule out abuse as the etiology for bruising or

2

bleeding. Similarly, the presence of a history of trauma (accidental or nonaccidental) does not exclude the presence of a bleeding disorder or other medical condition.

RECOMMENDED EVALUATION FOR BLEEDING DISORDERS IN SUSPECTED CHILD ABUSE: SCIENTIFIC RATIONALE AND SUPPORTING EVIDENCE

Recommendations in this report are based on data summarized in the accompanying technical report.²²

To determine the need for testing for bleeding disorders in children with suspicious bruising, recommendations are based on evidence that distinguishes accidental bruising from abusive bruising in children without bleeding disorders and evidence that characterizes bruising in children with congenital bleeding disorders. For suspicious bruising, the testing strategy was determined by the prevalence of the bleeding disorder. For suspicious ICH, the



FIGURE 1

Recommended pathway for evaluation of possible bleeding disorders when child abuse is suspected. *Child with age or developmentally related immobility.





oria Me

recommended testing strategy was based on the prevalence of specific bleeding disorders and evidence detailing the probability of ICH and, if possible, SDH, in certain clinical situations.

CHILD MEDICAL AND FAMILY HISTORY

Recommendation 1: If a child has bruising/bleeding concerning for abuse, a thorough medical history of the child and family history should be obtained. However, the lack of a history of bruising/bleeding symptoms does not rule out the possibility of a bleeding disorder.^{19–21}

Although a medical history of signs suggestive of a bleeding disorder, such as significant bleeding after a circumcision or other surgery, epistaxis, bleeding from the umbilical stump, or excessive bleeding after dental procedures, increases the possibility of a bleeding disorder, the absence of such a history does not rule out the presence of a bleeding disorder. If there is a family history of a specific bleeding disorder, testing for that specific disorder should be completed. Additionally, certain bleeding disorders have higher prevalence within specific populations, which may guide testing. Caregivers might state that their child "bruises easily." These statements are difficult to assess during an evaluation for possible abuse because they can be a sign of a bleeding disorder, a reflection of the child's (fair) skin tone, or a falsification to mask abuse. If children can provide a history, such a history should be obtained from them away from potential offending caregivers, if possible.

The child's medications should be documented, because certain drugs, such as nonsteroidal antiinflammatory drugs, some antibiotics, antiepileptics, and herbal medications, can affect the results of some tests that might be used to detect bleeding disorders, such as the platelet function analyzer (PFA-100 [Siemens Healthcare Diagnostics, Tarrytown, NY]) and platelet aggregation testing. In addition to bleeding disorders, the possibility of other medical causes of easy bruising or bleeding, such as Ehlers-Danlos syndrome, scurvy, cancer and other bone marrow infiltrative disorders, glutaric aciduria, and arteriovenous malformations, should be considered, as should a history of use of any restrictive or unusual diets, ingestions, or alternative therapies that may increase the likelihood of bleeding/bruising. Comprehensive descriptions of medical conditions that could be confused with child abuse and alternative therapies that may predispose to bleeding/bruising are beyond the scope of this report and can be found elsewhere.^{23–26}

ASSESSING THE NEED FOR AN EVALUATION FOR BLEEDING DISORDERS: BRUISING AND ICH

Bruising

Recommendation 2: If a child has bruising that is concerning for abuse, the assessment of the need for laboratory testing for bleeding disorders should focus on:

- the specific history offered to explain the bruising;
- the location and pattern of bruising; and
- mobility and developmental status of the child.^{13,17,27–30}

Any bleeding disorder can cause cutaneous bruising, and sometimes this bruising can be mild, can appear in locations that are considered suspicious for abuse,¹⁸ and can appear at any age. Children with inherited bleeding disorders have more and larger bruises than children without bleeding disorders.¹⁶

Recommendation 2a: If a child has any of the following factors, then an evaluation for a bleeding disorder is generally not needed:

- the caregivers' description of trauma sufficiently explains the bruising;
- the child or an independent witness can provide a history of abuse or nonabusive trauma that explains the bruising;
- object or hand-patterned bruising is present (highly consistent with abuse); or
- bruising to the ears, neck, or genitals (highly consistent with abuse).^{16,17,27,29,30}

Clinicians should consider that the injury history offered by caregivers might be purposefully misleading if the caregivers have caused the bruising by abusive means. In some cases, the constellation of findings, taken in conjunction with the

4

oria M

clinical history and physical examination, can be so strongly consistent with an abusive injury that further laboratory investigation for medical conditions is not warranted. For instance, a child with a patterned slap mark who describes being hit with an open hand does not require a laboratory evaluation for a bleeding disorder.

Recommendation 2b: If a nonmobile child has bruising, and there is no history of an independently witnessed accidental cause or a known medical cause, an evaluation for bleeding disorders should be conducted simultaneous to a child abuse evaluation.^{13,14,17,18,27,29}

Any bruising in a nonmobile child is highly concerning for abuse. Additionally, bruising in a young infant could also be the first presentation of a bleeding disorder. As such, in young infants or children with developmental delays with minimal or no mobility, who present with bruising, it is recommended that an evaluation for bleeding disorders occur simultaneous to an abuse evaluation. In nonmobile children, bleeding disorders can present with bruising or petechiae in sites of normal handling or pressure. Examples of this include:

- petechiae at clothing line pressure sites;
- bruising at sites of object pressure, such as in the pattern and location of infant seat fasteners; and
- excessive diffuse bruising/bleeding if the child has a severe bleeding disorder.

Absence of these examples does not rule out a bleeding disorder; however, their presence might increase the probability of a bleeding disorder.

Recommendation 2c: If a mobile child has bruising, then the possibility of abuse should be assessed using the locations and patterns of the bruising (Table 1).

In mobile children, bleeding disorders can cause bruising in areas generally considered suspicious for abuse, such as the buttocks or torso. Bruising to the ears, neck, or genitals is rarely seen in either accidental injuries or in children with bleeding disorders and is highly concerning for abuse.^{16,17,27,29,30}

 TABLE 1 Suspicion of Child Abuse in Ambulatory Children on the Basis of Characteristics of Bruises^{16,17,27-30,43}

Less Suspicious for Child Abuse	More Suspicious for Child Abuse
Forehead/nose/chin (facial T)	Location
Elbows	Cheeks
Lower arms	Angle of the jaw
Hips	Ears
Shins	Neck
Ankles	Upper arms
	Torso
	Hands
	Genitalia
	Buttocks
	Pattern
	Slap or hand marks
	Object marks
	Bite marks
	Bruises in clusters
	Multiple bruises of uniform shape
	Large cumulative size of bruising
	Petechial bruising ^a

^a Petechial bruising may also be suggestive of a bleeding disorder, particularly platelet function disorders.

ICH

Recommendation 3: If a child has ICH concerning for abuse, then an evaluation for bleeding disorders should be conducted (see Recommendation 9). Exceptions to required evaluation can include:

- independently witnessed or verifiable trauma (abusive or nonabusive); or
- other findings consistent with abuse, such as fractures, burns, or internal abdominal trauma.

The decision to conduct an evaluation for bleeding disorders can be made on a case-by-case basis depending on case specific factors. Excepting obvious known trauma, ICH, particularly SDH, in a nonmobile child is highly concerning for child abuse.

Children can suffer ICH, such as a small SDH or an epidural hematoma underlying a site of impact, from a short fall. However, short falls rarely result in significant brain injury.³¹ Birth trauma and some medical conditions can also result in ICH, including SDH, in infants. No studies have systematically compared the presentation, clinical findings, patterns or locations of ICH, or presence of retinal hemorrhages found in children with bleeding disorders to those found in children in whom abusive head trauma (AHT) is diagnosed. However, bleeding disorders can cause ICH in any part of the cranial contents and can cause spontaneous ICH, including SDH.¹⁵ Up to 12% of children and young adults with bleeding disorders have had ICH (traumatic, spontaneous, or otherwise) at some time.^{32,33}

Other Bleeding Symptoms

Recommendation 4: Children with conditions such as hematemesis, hematochezia, or oronasal bleeding as presenting signs should be evaluated on a case-by-case basis for possible abuse.

Caregiver-fabricated illness in a child, inflicted trauma, and/or medical conditions can cause any of these findings. A hematologist may be consulted to determine the necessity of an evaluation for bleeding disorders in a specific circumstance.

LABORATORY TESTS FOR BLEEDING DISORDERS

Recommendation 5: If performing tests for bleeding disorders in a child who has findings concerning for abuse, tests should be chosen on the basis of their ability to detect specific bleeding disorders that may cause the findings. Whole blood clotting assays, such as the thromboelastograph or rotational thromboelastography, should not be used as part of a testing strategy for bleeding disorders in the setting of possible abuse. Bleeding time is not a helpful test for diagnosing specific bleeding disorders.²²

Bleeding disorders that can produce patterns of bruising or bleeding that may mimic abuse include coagulation factor deficiencies/abnormalities, fibrinolytic defects, defects of fibrinogen, and platelet disorders. Table 2 contains a listing of the most common bleeding disorders in children and characteristics of potential testing strategies for each disorder. Most factor deficiencies can be detected by the prothrombin time (PT) and activated partial thromboplastin time (aPTT). However, von Willebrand disease (VWD) and factor XIII deficiency are not reliably detected by these tests. Additionally, mild deficiencies in factor VIII or factor IX (mild hemophilia) might not cause abnormalities in the aPTT, and, if testing for these conditions is desired, a specific factor level is necessary. Fibrinolytic defects can cause significant bleeding/bruising but are extremely rare and require

specific testing. Defects of fibrinogen are also rare and can be detected by the fibrinogen concentration and thrombin time.

Mild platelet disorders are those that typically result in mild mucocutaneous bleeding/bruising, menorrhagia, and/or postsurgical bleeding.²² The prevalence of mild platelet disorders is unknown, and testing for mild platelet disorders is challenging. The most common clinical presentations include bruising and mucocutaneous bleeding. The prevalence of ICH in mild platelet disorders is unknown but is likely to be low. Platelet aggregation testing, best performed by a specialized laboratory and interpreted by a pediatric hematologist, requires a relatively large volume of blood.³⁴ A PFA-100 can evaluate for many platelet function disorders, including more severe types, such as Bernard Soulier syndrome and Glanzmann thrombasthenia, as well as many types of VWD. However, the PFA-100 is not an effective test for some types of VWD and milder platelet abnormalities. Individual patient characteristics, such as hematocrit, platelet count, pregnancy, age, multisystem trauma, sepsis, and medications, can affect the results of the PFA-100. Accurate diagnosis often requires additional testing, such as specific VWD testing or platelet aggregation testing.^{34,35} Assessment of the results of a PFA-100 and the need for further testing are best accomplished in consultation with a pediatric hematologist.

Vitamin K Deficiency

Recommendation 6: If an infant, typically younger than 6 months, has bleeding/bruising findings concerning for abuse and a prolonged PT, provision of vitamin K at birth should be confirmed and/ or testing for vitamin K deficiency should be performed.

Factor athornantines/efficienciesWUD type 1Tper 100ADFFA-100*Sn = 79-66 ¹ Sp =PW =WD type 2AUncommonAD or ARFFA-100*Sn = 94-100*Sp = 99*0WD type 2BUncommonAD or ARFFA-100*Sn = 94-96 ¹ Sp =PW =WD type 2AUncommonAD or ARFFA-100*Sn = 94-91*5Sn = 94-91*5WD type 2AUncommonAD or ARFFA-100*Sn = 94-91*5Sn = 94-91*5WD type 2AUncommonAD or ARFFA-100*Sn = 94-91*5Sn = 94-91*5WD type 2AUncommonAR or compoundPFA-100*Sn = 94-91*5Sn = 94-91*5WD type 2AUncommonAR or compoundPFA-100*Sn = 94-91*5Sn = 94-91*5WD type 2A1 perNANametroxyddesSn = 94-100*5Sn = 94-100*5Factor II deficitory1 per 1 millionAR or compoundPFA-10*5Sn = 94-100*5Sn = 94-100*5Factor II deficitory1 per 1 millionAR or compoundPFA-10*5Sn = 94-100*5Sn = 94-100*5Factor II deficitory1 per 1 millionAR or compoundPFA-10*5Sn = 94-100*5Sn = 94-100*5Factor II deficitory1 per 1 millionAR or compoundPFA-10*5Sn = 94-100*5Sn = 94-100*5Factor II deficitory1 per 1 millionAR or compoundPFA-10*5Sn = 94-100*5Sn = 94-100*5Factor II deficitory1 per 1 millionAR or compoundPFA-10*5Sn = 94-100*5Sn = 94-100*5Fact	n Fr	equency	Inheritance	Initial Tests	Sn and Sp (%)	PPV, NPV (%)	Confirmatory Test
WUD type 1I per 1000ADFFA-100*Sn = 78-96° Sp =PPV =WUD type 2AUncommonAD or ARPFA-100*Sn = 94-100° Sp =PPV =WD type 2BUncommonADPFA-100*Sn = 94-90° Sp =PPV =WD type 2NUncommonAD or ARPFA-100*Sn = 94-90° Sp =PPV =WD type 2NUncommonAD or ARPFA-100*Sn = 94-90° Sp =PPV =WD type 2NUncommonAD or ARPFA-100*Sn = 94-90° Sp =PPV =WD type 2NUncommonAR, or compoundPFA-100*Sn = 94-90° Sp =PPV =WD type 2NUncommonAR, or compoundPFA-100*Sn = 94-90° Sp =PPV =WD type 31 perTomonAR, or compoundPFA-100*Sn = 94-90° Sp =PPV =WD type 31 perTomonAR, or compoundPFA-100*Sn = variablePPV =WD type 31 per 1 millionARPF1-10*Sn = variablePPV =Combined ExtervyI per 1 millionARPF1Sn = variableCombined Extervy1 per 1 millionARPT1PRSn = variableCombined Extervy1 per 1 millionARPT1Sn = variableControminion1 per 1 millionARPT1Sn = variableControminion2 artiblePNSn = variablePNControminion2 artiblePNSn = variableControminion2 artibleNANANAControminion2 ar	abnormalities/efficiencies						
W0 type 2AUncommonA0 or AR $FA+100^{\circ}$ $Bn = 94-00^{\circ}$ Sp = $PV =$ W0 type 2BUncommonA0 or AR $FA+100^{\circ}$ $Bn = 94-97^{\circ}$ Sp = $PV =$ W0 type 2MUncommonA0 or AR $FA+100^{\circ}$ $Bn = 94-97^{\circ}$ Sp = $PV =$ W0 type 2MUncommonA0 or AR $FA+100^{\circ}$ $Bn = 94-97^{\circ}$ Sp = $PV =$ W0 type 2MUncommonAR, or compound $PF1-100^{\circ}$ Sp = $PV =$ W0 type 2MUncommonAR, or compound $PF1-100^{\circ}$ Sp = $PV =$ W0 type 2MUncommonAR, or compound $PF1-100^{\circ}$ Sp = $PV =$ W0 type 2MUncommonAR, or compound $PF1-100^{\circ}$ Sp = $PV =$ W0 type 2MUncommonAR, or compound $PF1-100^{\circ}$ Sp = $PV =$ W1 type 2MThe terroxydotePF1-100^{\circ} Sp = $PV =$ Factor V deficiencyThe terroxydoteAR $PT1-PT1$ PT CondiciencyThe terroxydotePT1-PT1 PT PT CondiciencyThe terroxydotePT1-PT1 PT PT CondiciencyThe terroxydotePT1-PT1 PT PT CondiciencyThe terroxydotePT1-PT1 PT PT Condici	pe 1 1 per 10	00	AD	PFA-100 ^a	Sn = 79–96, ^b Sp = 88–96 ^b	PPV = 93.3, NPV = 98.2	Wantigen, ^c VWF activity, vW multimer analysis, forten vill optimity.
W00 type 28UnommonA0 $FFA100^{\circ}$ $Sn = 95-96^{\circ}$ $Sn = 94-97^{\circ}$ $Sn = 94-100^{\circ}$ $Sn = 24-100^{\circ}$	pe 2A Uncomm	ио	AD or AR	PFA-100 ^a	Sn = 94–100, ^b Sp = 88–96 ^b	PPV = 93.3, NPV = 98.2	VWantigen, ^c VWF activity, vW multimer analysis, factor VIII activity
W00 type 2MUncommonA0 or AR $FA : 100^{\circ}$ $Sn = 94 - 61^{\circ}$, $Sp =$ $PW =$ W00 type 2NUncommonAR or compound PTT MAW00 type 2NUncommonAR, or compound PTT MAW00 type 2NUncommonAR, or compound PTT PT W00 type 31 per PR , or compound PTT PT W00 type 31 per PR , or compound PTT PT M00 type 31 per PR PR PR Factor 11 deficiencyEstimated 1 per 1-2 PR PR Factor V1 deficiency1 per 1 million AR PTT PT Factor V1 deficiency1 per 1 million AR PTT PT Factor V1 deficiency1 per 1 million AR PTT PT Factor V11 deficiency1 per 1 million AR PTT PT Factor V11 deficiency1 per 1 million AR PTT PT Factor V11 deficiency1 per 1 million AR PTT PT Factor V11 deficiency1 per 2000 male AR PTT PT Factor V11 deficiency1 per 2000 male AR PTT PT Factor V11 deficiency1 per 2.5 million AR PTT PT Factor V11 deficiency1 per 2.5 million AR AR AR Factor V11 deficiency1 per 2.5 million AR AR AR Factor V11 deficiency1 per 2.5 million AR AR AR Factor	pe 2B Uncomm	ю	AD	PFA-100 ^a	Sn = 93–96, ^b Sp = 88–96 ^b	PPV = 93.3, NPV = 98.2	Wantigen, ^c VWF activity, vW multimer analysis, factor VIII activity
W00 type 2N Uncommon AR, or compound heterozygote PFA-100 ⁶ NA W00 type 3 1 per 30000-1000000 R, or compound heterozygote PFA-100 ⁶ Sn = 94-100 ¹⁶ Sp = PVV = Factor II daficiency (porthrombin) Externated 1 per 1-2 aPT, PT (may be million Sn = variable Sn = variable Factor VI daficiency (prothrombin) Extern V deficiency (prothrombin) ER PT, PT Sn = variable PVV = Factor VI deficiency (afficiency factor VI deficiency factor VI deficiency Tern Timilion AR PT Sn = variable PVV = Factor VI deficiency factor VI deficiency 1 per 30000-500000 AR PT Sn = variable PVV = Factor VI deficiency factor VI deficiency 1 per 30000-500000 AR PT Sn = variable Factor VI deficiency factor VI deficiency 1 per 30000-500000 AR PT Sn = variable Factor VI deficiency factor VI deficiency 1 per 30000-500000 AR PT Sn = variable Factor VI deficiency 1 per 1 million AR PT Sn = variable Sn = variable Factor VI defi	pe 2M Uncomm	ю	AD or AR	PFA-100 ^a	Sn = 94–97, ^b Sp = 88–96 ^b	PPV = 93.3, NPV = 98.2	Wantigen, ^c VWF activity, vW multimer analysis, factor VIII activity
W00 type 3 1 per 300000-1000000 AR, or compound heterozygote PA, 100 ⁴ Sn = 94-100 ⁴ Sp = PV = Factor II deficiency Estimated 1 per 1-2 aPT, PT (may be mormal) Sn = variable Sn = variable Sn = variable (prothrombin) million AR aPT, PT Sn = variable Sn = variable (prothrombin) million AR aPT, PT Sn = variable (prothrombin) million AR aPT, PT Sn = variable (prothrombin) million AR aPT, PT Sn = variable (combined Factor VI 1 per 1 million AR aPT, PT Sn = variable factor VII deficiency 1 per 5000 male births X-linked aPT Sn = variable factor VII deficiency 1 per 2000 male births X-linked aPT Sn = variable factor VII deficiency 1 per 100000 AR aPT Sn = variable factor VII deficiency 1 per 100000 AR aPT Sn = variable factor VII deficiency 1 per 100000 AR AR AT factor VII deficiency 1 per 100000 AR NA Sn = variable factor VII deficiency 1 per 100000 AR NA NA	pe 2N Uncomm	on	AR, or compound heterozvéote	аРТТ	NA	NA	VWF-factor VIII binding
Factor II deficiency (prothrombin)Estimated 1 per 1–2 millionaPT, PT (may be normal)Sin = variable normal)factor V deficiency (prothrombin)1 per 1 millionAR aPT, PTaPT, PT sin = variableSin = variable onormal)factor VIII factor VIII deficiency1 per 1 millionAR aPT, PTPTSin = variable sin = variablefactor VIII deficiency1 per 1 millionAR aPTPT aPTSin = variable sin = variablefactor VIII deficiency1 per 5000 male births birthsXIInked aPTTPT Sin = variablefactor VIII deficiency1 per 20 000 male births birthsXIInked aPTTPT Sin = variablefactor VIII deficiency1 per 20 000 male births birthsXIInked aPTTPT Sin = variablefactor VIII deficiency1 per 20 000 male birthsARPT aPTTSin = variable sin = variablefactor VIII deficiency1 per 1 millionARARARSin = variable aPTTfactor VIII deficiency1 per 100000ARARNANAfactor VIII deficiency1 per 100000ARNANAfactor VIII deficiency1 per 20000ARNANAfactor VIII	pe 3 1 per 300 00	01 000 000	AR, or compound heterozygote	PFA-100 ^a	$Sn = 94-100,^{b} Sp = 88-96^{b}$	PPV = 93.3, NPV = 98.2	Wwantigen, ^c ristocetin cofactor, WF multimer analysis, factor VIII activity
Factor V deficiency combined Factor ViI per 1 millionAR AaPT, PT ASn = variable seriableCombined Factor VI factor VIII1 per 1 millionAR AaPT, PTSn = variablefactor VIII deficiency1 per 1 millionAR APTSn = variablefactor VIII deficiency1 per 300 000–500 000AR APT ASn = variableFactor VII deficiency1 per 5000 male births birthsX-linked AaPTT ASn = variableFactor VII deficiency1 per 20 000 male birthsX-linked ARaPTT APTT APTTSn = variableFactor VII deficiency1 per 1 million birthsAR ARaPTT, PT, RVVSn = variableFactor XI deficiency1 per 1 million birthsAR 	II deficiency Estimate 	d 1 per 1–2 		aPTT, PT (may be 	Sn = variable	NA	Factor II activity ± antigen
deficiency Terr Sn = variable Factor VII deficiency 1 per 500 male births X-linked aPTT Sn = variable Factor VII deficiency 1 per 500 male births X-linked aPTT Sn = variable Factor VII deficiency 1 per 20 000 male X-linked aPTT Sn = variable Factor VII deficiency 1 per 1 million AR aPTT, PT, RVV Sn = variable Factor XI deficiency 1 per 1 million AR aPTT, RVV Sn = variable Factor XI deficiency 1 per 1 million AR aPTT, RVV Sn = variable Factor XI deficiency 1 per 1 million AR NA NA Factor XII deficiency 1 per 2-5 million AR NA NA Fibrinolytic defects 1 per 2-5 million AR NA NA Albrinogenemia Albrinogenemia 1 per 500000 AR NA NA NA Albrinogenemia 1 per million AR NA NA NA Albrinogenemia 1 per million AR NA	V deficiency 1 per 1 i ned Factor V/ 1 per 1 i r VIII	million million	AR AR	артт, рт артт > рт	Sn = variable Sn = variable	NA NA	Factor V activity Factor V and factor VIII activities
Factor VII deficiency1 per 300 000–500 000ARPTSn = variableFactor VII deficiency1 per 5000 male birthsX+InkedaPTTSn = variableFactor IX deficiency1 per 20 000 maleX+InkedaPTTSn = variableFactor IX deficiency1 per 1 millionARaPTT, PT, RVVSn = variableFactor XII deficiency1 per 1 millionARaPTT, PT, RVVSn = variableFactor XII deficiency1 per 1 millionARaPTT, PT, RVVSn = variableFactor XII deficiency1 per 2-5 millionARNANAFibrinolytic defectsARNANAFibrinolytic defects-ARNANANAFibrinolytic defects-ARNANANAFibrinolytic defects-ARARNANAFibrinolytic defects-ARNANANAFibrinolytic defects-ARNANANAFibrinolytic defectsARNANAFibrinolytic defectsARNANAFibrinolytic defectsNANAFibrinolytic defectsNANAFibrinolytic defectsNANAFibrinolytic defectsNANAFibrinolytic defectsNANAFibrinolytic defects <t< td=""><td>iencv</td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	iencv						
Factor VIII deficiency 1 per 500 male births X-linked aPTT Sn = variable Factor IX deficiency 1 per 20 000 male X-linked aPTT Sn = variable Factor X deficiency 1 per 1 million AR aPTT, PT, RVV Sn = variable Factor X deficiency 1 per 1 million AR aPTT, PT, RVV Sn = variable Factor XI deficiency 1 per 100 000 AR aPTT Sn = variable Factor XII deficiency 1 per 100 000 AR NA NA Fibrinolytic defects -40 reported cases AR IEG/ROTEM Sn = variable cator XIII deficiency 1 per 2-5 million AR NA NA CPAI-1) Very rare AR NA NA deficiency 1 per 500 000 AR NA NA Defects of fibrinogenemia 1 per 500 000 AR PT, aPTT Sn = variable Afbrinogenemia 1 per million AD PT, aPTT Sn = variable Afbrinogenemia 1 per million AD PT, aPTT Sn = variable Afbrinogenenemia 1 per million AD<	VII deficiency 1 per 30	0 000500 000	AR	РТ	Sn = variable	NA	Factor VII activity
DefectionDeficiency <t< td=""><td>VIII deficiency 1 per 50 IX deficiency 1 ner 20</td><td>00 male births 000 male</td><td>X-linked X-linked</td><td>aPTT aPTT</td><td>Sn = variable Sn = variable</td><td>NA</td><td>Factor VIII activity Factor IX activity</td></t<>	VIII deficiency 1 per 50 IX deficiency 1 ner 20	00 male births 000 male	X-linked X-linked	aPTT aPTT	Sn = variable Sn = variable	NA	Factor VIII activity Factor IX activity
Factor X deficiency1 per 1 millionARaPT, PT, RVVSn = variableFactor XI deficiency1 per 100 000ARaPTSn = variableFactor XIII deficiency1 per 2–5 millionARNANAFibrinolytic defects40 reported casesARTEG/ROTEMSn = variablecv2 antiplasmin40 reported casesARTEG/ROTEMSn = variabledeficiency40 reported casesARNANADefects of fibrinogenARNANAAfbrinogenemia1 per 500 000ARPT, aPTTSn = variableAfbrinogenemiaLess thanAD, occasionally ARThrombin time,Sn = variableDysfibrinogenemia1 per millionAD, occasionally ARThrombin time,Sn = variableDysfibrinogenemia1 per millionAD, occasionally ARThrombin time,Sn = variable	births			-			ו מנוסו וא מנוזונץ
Factor XI deficiency1 per 100 000ARaPTTSn = variableFactor XIII deficiency1 per 2–5 millionARNANAFibrinolytic defects ~ 40 reported casesARTEG/ROTEMSn = variable α^{-2} antiplasmin ~ 40 reported casesARTEG/ROTEMSn = variable α^{-1} Very rareARNANA α^{-1} Very rareARNANA α^{-1} Very rareARNANA α^{-1} Lefects of fibrinogenARNANA α^{-1} Lees thanADPT, aPTTSn = variable α^{-1} Less thanADPT, aPTTSn = variable α^{-1} Iper millionAD, occasionally ARThrombin time,Sn = variable α^{-1} 1 per millionAD, occasionally ARThrombin time,Sn = variable α^{-1} 1 per millionAD, occasionally ARThrombin time,Sn = variable	X deficiency 1 per 1 r	million	AR	aptt, pt, rvv	Sn = variable	NA	Factor X activity
Factor XIII deficiency Tector XIII deficiency NA NA Fibrinolytic defects -40 reported cases AR TEG/ROTEM Sn = variable & 2 antiplasmin ~40 reported cases AR TEG/ROTEM Sn = variable deficiency (PAI-1) Very rare AR NA NA Defects of fibrinogen AR NA NA Aftbrinogenemia 1 per 500 000 AR PT, aPTT Sn = high Hypofibrinogenemia Less than AD PT, aPTT Sn = variable Dysfibrinogenemia 1 per million AD, occasionally AR Thrombin time, Sn = variable	XI deficiency 1 per 10	0000	AR	aPTT	Sn = variable	NA	Factor XI activity
&-2 artiplasmin ~40 reported cases AR TEG/R0TEM Sn = variable deficiency (PAI-1) Very rare AR NA (PAI-1) Very rare AR PT B Afbrinogenemia 1 per 500 000 AR PT, aPTT Sn = high Hypofibrinogenemia Less than AD PT, aPTT Sn = variable Dysfibrinogenemia 1 per million AD; occasionally AR Thrombin time, Sn = variable	Alli denciency I per 2- vtic defects	uoiiiim c	AK	NA	NA	NA	Factor Alli activity
(PAI-1) Very rare AR NA Defects of fibrinogen Aftbrinogenemia 1 per 500 000 AR PT, aPTT Sn = high Aftbrinogenemia 1 per 500 000 AR PT, aPTT Sn = variable Hypofibrinogenemia 1 per 500 000 AR PT, aPTT Sn = variable Dysfibrinogenemia 1 per million AD PT, aPTT Sn = variable Dysfibrinogenemia 1 per million AD; occasionally AR Thrombin time, Sn = variable	iplasmin ~40 rep. iencv	orted cases	AR	TEG/ROTEM	Sn = variable	NA	α -2 antiplasmin activity
Defects of Inductiogen Affbrinogenemia 1 per 500 000 AR PT, aPTT Sn = high Hypofibrinogenemia Less than AD PT, aPTT Sn = variable affbrinogenemia 1 per million AD; occasionally AR Thrombin time, Sn = variable Dysfibrinogenemia 1 per million AD; occasionally AR Thrombin time, Sn = variable	Very rar		AR	NA	NA	NA	PAI -1 antigen and activity
Hypofibrinogenemia i per account AD PT, aPTT Sn = variable afibrinogenemia afibrinogenemia AD; occasionally AR Thrombin time, Sn = variable Dysfibrinogenemia 1 per million AD; occasionally AR Thrombin time, Sn = variable fibrinogen level	01 IIDFINOSEII Joanamia 1 nar 501		AB	рт артт	Sn = hidh	NA	Eihrinogan laval
afibrinogenemia Dysfibrinogenemia 1 per million AD; occasionally AR Thrombin time, Sn = variable fibrinogen level	vrinogenemia Less that		AD	PT, aPTT	Sn = variable	NA	Thrombin time, fibrinogen
Dysfibrinogenemia 1 per million AD; occasionally AR Thrombin time, Sn = variable fibrinogen level	afibrir	nogenemia					activity
	inogenemia 1 per mi	llion	AD; occasionally AR	Thrombin time, fibrinogen level	Sn = variable	NA	Thrombin time, fibrinogen antigen and activity level comparison,

6

TABLE 2 Continued						
Condition	Frequency	Inheritance	Initial Tests	Sn and Sp (%)	PPV, NPV (%)	Confirmatory Test
Platelet disorders						
ПР	Age-related	NA	CBC	Sn = high	NA	Antiplatelet Ab (rarely needed)
Glanzmann thrombasthenia	Very rare	AR	PFA-100 ^a	Sn = 97-100	NA	Platelet aggregation testing flow cytometry
Bernard Soulier syndrome	Rare	AR	PFA-100 ^a	Sn = 100	NA	Platelet aggregation testing flow cytometry
Platelet release/	Unknown, more	Variable	PFA-100 ^a	Sn = 27 - 50	NA	Platelet aggregation and
storage disorders	common than other					secretion, electron
	platelet function					microscopy, molecular
	disorders					and cytogenetic testing
AD, autosomal dominant; AR, ROTEM, rotational thromboela	autosomal recessive; CBC, complet stometry; RVV, Russell viper venom	e blood count; ITP, im (test); Sn, sensitivity;	Imune thrombocytopenia; N Sp, specificity; TEG, thromb	 IA, not available or not applicable; NPV, poelastography; vW, von Willebrand; VWs 	negative predictive value; PA ntigen, von Willebrand antige	 plasminogen activator inhibitor-1; PPV, positive predictive value; vWF, von Willebrand factor.

and mild platelet abnormalities. forms of VWD Testing may miss some PFA-100 sensitivity and specificity provided for informational purposes.

Values derived from data before 2008 National Institutes of Health consensus guidelines. Sensitivity and specificity using current diagnostic cutoffs unknown but would be expected to have higher specificity with lower sensitivity. May be reasonable to proceed directly to diagnostic testing depending on availability. See accompanying technical report for detailed discussion.²² Vitamin K deficiency in younger infants can result in bleeding in the skin or from mucosal surfaces from circumcision, generalized ecchymoses, large intramuscular hemorrhages, or ICH. Because of the widespread provision of vitamin K at birth, vitamin K deficiency bleeding (VKDB) is rare; however, not all states require vitamin K to be administered at birth, refusal of vitamin K by parents has increased, and some medical conditions predispose to VKDB.²² In VKDB, there is a prolonged PT and possibly aPTT for age. In patients who have already received vitamin K, fresh-frozen plasma, or specific factor replacement as treatment, measurement of proteins induced by vitamin K absence can confirm the diagnosis.36,37

COAGULATION TESTS: BRUISING AND ICH

Recommendation 7: Physicians who do not have the necessary resources available or who are not comfortable with evaluating for bleeding disorders in the context of possible child abuse should refer to a child abuse pediatrician, pediatric hematologist, or other physician who is capable of completing the evaluation.

The extent of laboratory evaluations performed by a physician may be affected by the availability of such tests to the physician and the physician's comfort or skill in interpreting the test(s) in the context of the child's findings. Additionally, because coagulation testing results can be altered by delay of processing after drawing the sample or by relative inexperience in running the assay, it may be better to have testing performed at a reference laboratory. For cases in which the recommended tests are not readily available, the authors recommend referral.

Coagulation Tests in the Setting of Suspicious Bruising

Recommendation 8: If a child has bruising concerning for abuse that necessitates an evaluation for bleeding disorders, the following tests should be obtained:

- PT;
- aPTT;
- VWF antigen;
- VWF activity (Ristocetin cofactor);
- Factor VIII activity level;
- Factor IX activity level; and
- complete blood count with platelet count.

IF TEST RESULTS ARE ABNORMAL OR EXPANDED/DETAILED TESTING IS NECESSARY OR PREFERRED, CONSULTATION WITH A PEDIATRIC HEMATOLOGIST IS RECOMMENDED (FIG 1).

The initial testing panel in a patient who presents with bruising evaluates for idiopathic thrombocytopenic purpura, all factor deficiencies (except factor XIII deficiency), and VWD (Fig 1). It does not evaluate for extremely rare conditions, including factor XIII deficiency, defects of fibrinogen, and fibrinolytic defects. This strategy also does not test for extremely rare platelet disorders and more common, but relatively more difficult to diagnose, platelet function disorders.

Recommendation 8a: If a child who has bruising suspicious for abuse is removed from a potentially dangerous setting where the abuse likely occurred, a thorough physical examination should be performed in the weeks after removal. If that examination reveals minimal bruising and/or bruising only in locations of common accidental bruises, abuse is supported as the cause of the original suspicious bruising.

8

Each case should be evaluated individually, considering the totality of findings, and with the understanding of the need to balance safety with the emotional trauma of removing a child from his or her home. Bleeding disorders are generally permanent conditions that do not result in abatement after a change in caregivers. One exception to this is immune thrombocytopenia which is a transient. often selfresolving bleeding disorder. Testing for immune thrombocytopenia with a platelet count is necessary at the time of presentation with bruises.

Coagulation Tests in the Setting of ICH

Specific data regarding the prevalence of bleeding disorders in the population of children with ICH are not available. However, there are data regarding the probability of specific bleeding disorders to cause ICH, and in some cases, specifically SDH. If the prevalence of a condition and the frequency of a presentation of that condition are known, the probability of that specific condition (bleeding disorder) resulting in the specific presentation (ICH or, more specifically, SDH) can be determined (Table 3). Some probabilities are so low as to preclude calculation. Data summarizing the prevalence and probability of SDH in children younger than 2 years with mild, moderate, and severe deficiencies of factors VIII and IX on the basis of history of trauma are in Table 4.

Recommendation 9: If a child has ICH concerning for abuse and testing for bleeding disorders is conducted, then the following initial testing panel is recommended (Fig 1):

- PT;
- aPTT; and

• complete blood count with platelet count.

The initial testing panel for ICH evaluates for most factor deficiencies. Although the prevalence of severe hemophilia in females is significantly lower than that in males, it does occur, and will be detected by aPTT. This panel does not include testing for mild and moderate deficiencies of factors VIII and IX. This panel also does not test for factor XIII deficiency. Consideration should be given to prevalence in certain populations because it is estimated that one-third of the human population with severe congenital deficiency of factor XIII deficiency is in Iran.²² The most frequent type of ICH in factor XIII deficiency is intraparenchymal hemorrhage.²² Other conditions for which testing is not included in the suggested initial panel include VWD, fibrinolytic defects, and disorders of fibrinogen. These conditions either have not been associated with ICH or they are so rarely the cause of ICH that testing for the conditions is generally not helpful.

Recommendation 9a: In ICH concerning for abuse, testing for mild and moderate hemophilia, d-dimer, fibrinogen, and VWD may be necessary on the basis of specific clinical scenarios. If there is a history of trauma, testing for mild hemophilia (levels of factor VIII and factor IX) should be performed. If there is neurologic compromise, testing for d-dimer and fibrinogen should be performed (Fig 1).

Mild or moderate hemophilia may result in SDH after trauma but is not a reasonable explanation for spontaneous SDH. Mild hemophilia, which might be missed if only a PTT test is ordered, can be detected by measuring specific activity levels of factor VIII and factor IX. If there is concern that a history of trauma may be offered at a time subsequent

TABLE 3	Probabilities	for	Congenital	Coagulopathies	to	Cause	ICH
171222 0	110000000000000000000000000000000000000		oongointui	oougulopulliloo		0000	1011

Condition	Prevalence of Condition	Prevalence of ICH	Probability ^a
VWD	1 per 1000	Extremely rare	Low ^b
Factor II deficiency	1 per 1 million	11%	1 per 10 million
Factor V deficiency	1 per 1 million	8% of homozygotes	1 per 10 million homozygotes
Combined factors V and VIII deficiencies	1 per 1 million	2%	1 per 50 million
Factor VII deficiency	1 per 300 000	4%-6.5%	1 per 5 million
Factor VIII deficiency (all) ^c	1 per 9500 males	7.0%	1 per 140000
Severe	1 per 20000 males	9.1%	1 per 220 000
Moderate	1 per 40 000 males	4%	1 per 1 million
Mild	1 per 30 000 males	2.8%	1 per 1.1 million
Factor IX deficiency (all) ^c	1 per 34 000 males	7.6%	1 per 450 000
Severe	1 per 95000 males	10.7%	1 per 885000
Moderate	1 per 110000 males	3.4%	1 per 3.1 million
Mild	1 per 120 000 males	8%	1 per 1.5 million
Factor X deficiency	1 per 1 million	21%	1 per 5 million
Factor XI deficiency	1 per 1 million	Extremely rare	Low ^b
Factor XIII deficiency	1 per 2 million	33%	1 per 6 million
α-2 antiplasmin deficiency	Extremely rare	Not reported	Low ^b
Plasminogen activator inhibitor-1 deficiency (PAI-1)	Extremely rare	Common	Low ^b
Afibrinogenemia	1 per 500 000	10%	1 per 5 million
Dysfibrinogenemia	1 per 1 million	Single case report	Low ^b

The probability of having a specific bleeding disorder increases in the setting of a family history of that specific-named bleeding disorder or if the patient is from an ethnicity in which a specific bleeding disorder is more common (eg, Ashkenazi Jewish people and factor XI deficiency). PAI-1, plasminogen activator inhibitor-1.

^a "Probability" indicates the probability that an individual in the general population would have the following specific coagulopathy causing an ICH.

^b It is not possible to calculate a probability on the basis of the rarity of the occurrence.

^c Age-adjusted prevalence of all, severe, moderate, and mild deficiencies of factor VIII and IX were used. Probability is calculated for children younger than 4 years.

to the medical evaluation, consideration should be given to evaluating for deficiencies of factors VIII and IX at the time of the medical evaluation. The prevalence of mild and moderate hemophilia in females is unknown, and therefore, the recommendations for testing in the case of ICH do not differ on the basis of gender.²² If the child is acutely neurologically compromised, a d-dimer and fibrinogen are recommended because of the potential of disseminated intravascular coagulation (DIC). Because DIC can cause any type of bruising/bleeding, including ICH, the finding of DIC in the context of suspected child abuse could significantly change the clinical approach to a patient. In children with DIC and bleeding symptoms as the only finding concerning for abuse, consideration should be given to the multitude of primary causes of DIC, including trauma, and sepsis, among many others. Although not specifically included in the recommended testing panel, VWD has been associated with SDH after minor trauma in children who return to neurologic baseline.³⁸ VWD has not been demonstrated to cause spontaneous SDH and/or accompanying persistent neurologic compromise that may be confused with AHT.¹⁵ In some select cases, particularly those involving young children with SDH and no neurologic compromise in the setting of possible trauma, testing for VWD may be considered.

TABLE 4 Probabilities	for Hemophilia A (Factor VI	I deficiency) and B (Factor IX	(deficiency) to Cause SDH	in Children Younger Than 2 Years
------------------------------	-----------------------------	--------------------------------	---------------------------	----------------------------------

Condition	Prevalence of Condition ^a	Prevalence of Traumatic SDH	Probability ^b of Traumatic SDH	Prevalence of Spontaneous SDH	Probability ^b of Spontaneous SDH
Factor VIII deficiency (all)	1 per 9500 males	1%	1 per 1.2 million	1.1%	1 per 860 000
Severe	1 per 20 000 males	1%	1 per 2.2 million	1.8%	1 per 1.1 million
Moderate	1 per 40 000 males	1%	1 per 5.7 million	0%	Low ^c
Mild	1 per 30 000 males	1%	1 per 3 million	0%	Low ^c
Factor IX deficiency	1 per 34 000 males	0.9%	1 per 3.8 million	0.9%	1 per 3.8 million
(all)					
Severe	1 per 95 000 males	0%	Low	2%	1 per 4.8 million
Moderate	1 per 110 000 males	3%	1 per 4.4 million	0	Low ^c
Mild	1 per 120 000 males	0%	Low	0	Low ^c

^a Age-adjusted prevalence of all, severe, moderate, and mild deficiencies of factor VIII and factor IX were used.

^b "Probability" indicates the probability that an individual in the general population would have the following specific coagulopathy causing an ICH.

^c It is not possible to calculate a probability on the basis of the rarity of the occurrence.

Recommendation 9b: If blood products have been given to the patient, the definitive evaluation for bleeding disorders should be postponed until the transfused blood components are no longer in the patient's system (Table 5).

In general, waiting 7 half-lives until testing for a specific factor deficiency should be sufficient for depletion of transfused product. However, the clinical status of the patient should also be considered. In some cases, testing may be able to be performed sooner, if clinical suspicion is exceptionally high and need for treatment is paramount. Assistance from a pediatric hematologist should be considered in addressing the possibility of factor deficiencies after a transfusion has occurred.

When Testing Indicates a Possible Bleeding Disorder in the Context of an Abuse Evaluation

Abnormal laboratory test results require further evaluation for the possibility of false-positive results and/or the necessity for further testing. The aPTT can be falsely prolonged in certain circumstances, such as in the presence of a lupus anticoagulant, or can be prolonged and might not indicate a true bleeding disorder, such as in factor XII deficiency or other contact factor

TABLE 5 Half-Lives of Coagulation Factors

Factor	Half-Life Postinfusion (h)
Fibrinogen	96-150
11	60
V	24
VII	4—6
VIII	11–12
IX	22
Х	35
XI	60
XIII	144–300
VWF	8-12

Republished with permission of McGraw Hill LLC, from Goodnight S, Hathaway W. *Disorders of Hemostasis and Thrombosis: A Clinical Guide*, second ed. New York, NY: McGraw-Hill Professional; 2001:497; permission conveyed through Copyright Clearance Center, Inc. VWF, von Willebrand factor.

10

deficiencies. In addition, patients who experience a traumatic brain injury often have a transient coagulopathy that does not reflect an underlying congenital disorder.³⁹ Coagulation tests are very sensitive to specimen handling and should be performed in laboratories experienced with these assays. Inappropriate collection and handling commonly lead to falsepositive results, and one should consider careful repeat testing. It may be reasonable to obtain a sample in a sodium citrate tube before transfusion. Clinical scenarios that may affect the results of testing should also be noted.

Additionally, consideration should be given to the likelihood of a preexisting bleeding disorder as the primary cause of a child's bleeding/bruising. For example, given the relatively high prevalence of VWD, it is inevitable that some children with VWD will be abused and present with bleeding/bruising symptoms. Determining the causative factor in these situations is challenging. Bruising is a common finding in VWD. If a child has test results consistent with VWD and bruising concerning for abuse, an absence of new concerning bruising in a different care setting over time is supportive of abuse as the cause of the previous concerning bruises. Most reported ICH in children with VWD would not be confused with typical abusive ICH.^{15,39–42} Given the rarity of ICH in VWD, particularly spontaneous ICH, testing consistent with VWD does not mean that ICH is definitively attributable to VWD.

Evidence Quality and Strength of Recommendation

The prevalence of a bleeding disorder (greater than 1 per 500 000) used for testing in cases of suspicious bruising is based on

expert opinion of the authors of this report. This level was chosen to detect reasonably common bleeding disorders. Similarly, the level of probability (greater than 1 per 5 million) for the initial testing for ICH was based on expert opinion to detect bleeding disorders that were extremely unlikely to cause an ICH. Using this level of probability minimizes the chances of misdiagnosing a bleeding disorder as AHT. Expert opinion was used for the testing recommendations for DIC and VWD on the basis of casespecific information. If more extensive testing is desired, a pediatric hematologist may be consulted. Although testing for some bleeding disorders may be costly, testing is necessary because bleeding disorders may manifest in ways that are difficult to otherwise distinguish from abuse.

CONCLUSIONS

Children who present with bleeding and bruising concerning for abuse require careful evaluation for the potential of bleeding disorders as a cause. No single panel of tests rules out every possible bleeding disorder. Given the rarity of most bleeding disorders and the possible presence of specific clinical factors that decrease the likelihood of a bleeding disorder causing a child's findings, extensive laboratory evaluation is usually not necessary. If a laboratory evaluation is conducted, tests should be chosen on the basis of the prevalence of the condition, patient and family history, blood volume required for testing, and in the case of ICH, probability of a bleeding disorder causing ICH. Testing can be further tailored on the basis of specific patient factors. Further consultation with a pediatric hematologist is recommended if expanded testing is necessary, if preliminary testing suggests the presence of a bleeding disorder, if testing is needed to rule

out a specific bleeding disorder, or if testing for very rare conditions is preferred.

Guidance for Pediatricians

Data used for recommendations in this report are summarized in the accompanying technical report.²² Specifically, evidence was used that distinguishes abusive from accidental bruising and that characterizes bruising in children with congenital bleeding disorders. Additionally, for ICH and, when possible, SDH, evidence was used that characterized the probability of ICH and/or SDH in certain clinical scenarios. Specific recommendations were included in this report to increase clarity. Below is guidance for pediatricians, each followed by its corresponding recommendations(s) within the report.

In children who have bruising or bleeding that is suspicious for abuse:

 Complete medical, trauma, and family histories, screening for unusual or restrictive diets, and a thorough physical examination are critical tools in evaluating for the possibility of abuse or medical conditions that predispose to bleeding/bruising. However, family and patient medical history alone have not been shown to effectively predict the presence of a bleeding disorder.

(Recommendation 1)

2. In each case, careful consideration of the possibility of a medical condition causing the bleeding/ bruising is essential. Specific elements of the history, developmental status of the child, and characteristics of the bleeding/bruising can be used to determine the need for a laboratory evaluation for bleeding disorders. (*Recommendations 2*, *2a, 2b, 2c, 3, 4*) 3. If the evaluation indicates a need for laboratory testing for bleeding disorders, initial testing is focused on the prevalence of the condition and potential of each specific condition to cause the specific findings in a given child (Fig 1). Tests should be chosen on the basis of their ability to detect specific bleeding disorders that may cause the findings. In some cases, testing may be tailored on the basis of the history, findings, and patient characteristics.

(Recommendations 5, 6, 8, 9, and 9a)

- 4. Consultation with child abuse pediatricians and/or pediatric hematologists should be strongly considered in children with bruising/bleeding concerning for abuse, including ICH and particularly in cases of SDH. (Recommendation 7)
- 5. Laboratory testing suggesting or indicating the presence of a bleeding disorder does not eliminate abuse from consideration. In children with bruising and laboratory testing suggestive of a bleeding disorder, a follow-up evaluation after a change in home setting can provide valuable information regarding the likelihood of a bleeding disorder causing the concerning findings.

(Recommendation 8a)

- Children with ICH often receive blood product transfusions. It is suggested that testing for bleeding disorders in these patients be delayed until elimination of the transfused blood clotting elements. (Recommendation 9b)
- 7. The discovery of new information regarding condition prevalence, laboratory testing, and clinical presentations of bleeding disorders is to be expected. Close collaboration with a pediatric

hematologist may be necessary. *(Recommendation 7)*

LEAD AUTHORS

James D. Anderst, MD, MS, FAAP Shannon L. Carpenter, MD, MS, FAAP Emily Killough, MD, FAAP Thomas Abshire, MD

CONSULTANTS

Eneida A. Mendonca, MD, PhD, FAAP, FACMI Stephen M. Downs, MD, MS, FAAP, FACMI

SECTION ON HEMATOLOGY/ONCOLOGY EXECUTIVE COMMITTEE, 2020–2021

Cynthia Wetmore, MD, PhD, FAAP, chairperson Carl Allen, MD, PhD, FAAP David Dickens, MD, FAAP James Harper, MD, FAAP Zora R. Rogers, MD, FAAP Juhi Jain, MD, FAAP Anne Warwick, MD, MPH, FAAP Amber Yates, MD, FAAP

PAST EXECUTIVE COMMITTEE MEMBERS

Jeffrey Hord, MD, FAAP Jeffrey Lipton, MD, PhD, FAAP Hope Wilson, MD, FAAP

STAFF

Suzanne Kirkwood, MS

COUNCIL ON CHILD ABUSE AND NEGLECT, 2020–2021

Suzanne B. Haney, MD, MS, FAAP, chairperson Andrea Gottsegen Asnes, MD, FAAP Amy R. Gavril, MD, MSCI, FAAP Rebecca Greenlee Girardet, MD, FAAP Nancy Heavilin, MD, FAAP Amanda Bird Hoffert Gilmartin, MD, FAAP Antoinette Laskey, MD, MPH, MBA, FAAP Stephen A. Messner, MD, FAAP Bethany Anne Mohr, MD, FAAP

Shalon Marie Nienow, MD, FAAP Norell Rosado, MD, FAAP

PAST COUNCIL ON CHILD ABUSE AND NEGLECT EXECUTIVE COMMITTEE MEMBERS

Sheila M. Idzerda, MD, FAAP Lori A. Legano, MD, FAAP Anish Raj, MD Andrew P. Sirotnak, MD, FAAP

LIAISONS

Heather C. Forkey MD, FAAP, Council on Foster Care, Adoption and Kinship Care Brooks Keeshin, MD, FAAP, American Academy of Child and Adolescent Psychiatry Jennifer Matjasko, PhD, Centers for Disease Control and Prevention Heather Edward, MD, Section on Pediatric Trainees **STAFF** Müge Chavdar, MPH

AMERICAN SOCIETY OF PEDIATRIC HEMATOLOGY/ONCOLOGY BOARD OF TRUSTEES, 2020–2021

Jorge Di Paola, MD (president) Patrick Leavey, MD, FAAP Doug Graham, MD, PhD Caroline Hastings, MD Nobuko Hijiya, MD Jeffrey Hord, MD, FAAP Dana Matthews, MD Betty Pace, MD Maria C. Velez, MD, FAAP Dan Wechsler, MD, PhD

PAST BOARD MEMBERS

Amy Billett, MD, FAAP Linda Stork, MD

STAFF

Ryan Hooker, MPT

ABBREVIATIONS

AHT: abusive head trauma
aPTT: activated partial thromboplastin time
DIC: disseminated intravascular coagulation
ICH: intracranial hemorrhage
PFA-100: platelet function analyzer
PT: prothrombin time
SDH: subdural hemorrhage
VKDB: vitamin K deficiency bleeding
VWD: von Willebrand disease

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2022 by the American Academy of Pediatrics

FINANCIAL/CONFLICT OF INTEREST DISCLOSURES: None

COMPANION PAPER: A companion to this article can be found online at www.pediatrics.org/cgi/doi/1542/peds.2022-059277.

REFERENCES

- Wood JN, French B, Song L, Feudtner C. Evaluation for occult fractures in injured children. *Pediatrics*. 2015;136(2):232–240
- Lindberg DM, Beaty B, Juarez-Colunga E, Wood JN, Runyan DK. Testing for abuse in children with sentinel injuries. *Pediatrics.* 2015;136(5):831–838
- Paroskie A, Carpenter SL, Lowen DE, Anderst J, DeBaun MR, Sidonio RF Jr. A two-center retrospective review of the hematologic evaluation and laboratory abnormalities in suspected victims of non-accidental injury. *Child Abuse Negl.* 2014;38(11):1794–1800
- Jackson J, Miller M, Moffatt M, Carpenter S, Sherman A, Anderst J. Bruising in children: practice patterns of pediatric hematologists and child abuse pediatricians. *Clin Pediatr (Phila)*. 2015;54(6): 563–569
- Howsam FZ, Perera L, Trounce J. 'Oral injury in child abuse'. *Arch Dis Child*. 2014;99(3):207

- Ulinski T, Lhopital C, Cloppet H, et al. Munchausen syndrome by proxy with massive proteinuria and gastrointestinal hemorrhage. *Pediatr Nephrol.* 2004;19(7):798–800
- Starr M, Klein EJ, Sugar N. A perplexing case of child abuse: oral injuries in abuse and physician reporting responsibilities. *Pediatr Emerg Care*. 2015; 31(8):581–583
- 8. Dorfman MV, Metz JB, Feldman KW, Farris R, Lindberg DM. ExSTRA Investigators. Oral injuries and occult harm in children evaluated for abuse. *Arch Dis Child*. 2018;103(8):747–752
- 9. Walton LJ, Davies FC. Nasal bleeding and non-accidental injury in an infant. *Arch Dis Child.* 2010;95(1):53–54
- 10. Anderst J, Kellogg N, Jung I. Is the diagnosis of physical abuse changed when Child Protective Services consults a child abuse pediatrics subspecialty group as a second

opinion? *Child Abuse Negl.* 2009; 33(8):481–489

- Scimeca PG, Cooper LB, Sahdev I. Suspicion of child abuse complicating the diagnosis of bleeding disorders. *Pediatr Hematol Oncol.* 1996;13(2):179–182
- McGuire L, Martin KD, Leventhal JM. Child abuse consultations initiated by child protective services: the role of expert opinions. *Acad Pediatr.* 2011; 11(6):467–473
- Sheets LK, Leach ME, Koszewski IJ, Lessmeier AM, Nugent M, Simpson P. Sentinel injuries in infants evaluated for child physical abuse. *Pediatrics*. 2013;131(4):701–707
- 14. Harper NS, Feldman KW, Sugar NF, Anderst JD, Lindberg DM. Examining Siblings To Recognize Abuse Investigators. Additional injuries in young infants with concern for abuse and apparently isolated bruises. *J Pediatr.* 2014;165(2): 383–388.e1

- Anderst JD, Carpenter SL, Presley R, et al. Relevance of abusive head trauma to intracranial hemorrhages and bleeding disorders. *Pediatrics*. 2018;141(5): e20173485
- Collins PW, Hamilton M, Dunstan FD, et al. Patterns of bruising in preschool children with inherited bleeding disorders: a longitudinal study. *Arch Dis Child*. 2017;102(12):1110–1117
- Pierce MC, Kaczor K, Aldridge S, O'Flynn J, Lorenz DJ. Bruising characteristics discriminating physical child abuse from accidental trauma. *Pediatrics*. 2010;125(1):67–74
- Jackson J, Carpenter SL, Anderst JD. Challenges in the evaluation for possible abuse: presentations of congenital bleeding disorders in childhood. *Child Abuse Negl.* 2012;36(2):127–134
- Bowman M, Riddel J, Rand ML, Tosetto A, Silva M, James PD. Evaluation of the diagnostic utility for von Willebrand disease of a pediatric bleeding questionnaire. *J Thromb Haemost.* 2009;7(8):1418–1421
- 20. Bidlingmaier C, Grote V, Budde U, Olivieri M, Kurnik K. Prospective evaluation of a pediatric bleeding questionnaire and the ISTH bleeding assessment tool in children and parents in routine clinical practice. *J Thromb Haemost.* 2012;10(7): 1335–1341
- Rodriguez V, Titapiwatanakun R, Moir C, Schmidt KA, Pruthi RK. To circumcise or not to circumcise? Circumcision in patients with bleeding disorders. *Haemophilia*. 2010;16(2):272–276
- 22. Carpenter SL, Abshire TC, Killough EF, Anderst JD. American Academy of Pediatrics, Section on Hematology/ Oncology, Council on Child Abuse and Neglect. Technical report: evaluation for conditions that predispose to bleeding when child abuse is suspected. *Pediatrics.* 2022;150(4):e2022059276
- 23. Brambilla A, Pizza C, Lasagni D, Lachina L, Resti M, Trapani S. Pediatric scurvy:

when contemporary eating habits bring back the past. *Front Pediatr.* 2018;6:126

- 24. Lake MB, Birmaher B, Wassick S, Mathos K, Yelovich AK. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. *J Child Adolesc Psychopharmacol.* 2000;10(1):35–38
- Sirotnak AP. Medical disorders that mimic abusive head trauma. In: Frasier L, Rauth-Farley K, Alexander R, Parrish R, eds. *Abusive Head Trauma in Infants* and Children. St Louis, MO: G W Medical Publishing; 2006:191–214
- Dinehart SM, Henry L. Dietary supplements: altered coagulation and effects on bruising. *Dermatol Surg.* 2005; 31(7 Pt 2):819–826, discussion 826
- Kemp AM, Dunstan F, Nuttall D, Hamilton M, Collins P, Maguire S. Patterns of bruising in preschool children–a longitudinal study. *Arch Dis Child.* 2015;100(5):426–431
- Hibberd O, Nuttall D, Watson RE, Watkins WJ, Kemp AM, Maguire S. Childhood bruising distribution observed from eight mechanisms of unintentional injury. *Arch Dis Child.* 2017;102(12): 1103–1109
- 29. Maguire S, Mann M. Systematic reviews of bruising in relation to child abusewhat have we learnt: an overview of review updates. *Evid Based Child Health.* 2013;8(2):255–263
- Maguire S, Mann MK, Sibert J, Kemp A. Are there patterns of bruising in childhood which are diagnostic or suggestive of abuse? A systematic review. *Arch Dis Child.* 2005;90(2):182–186
- 31. Chadwick DL, Bertocci G, Castillo E, et al. Annual risk of death resulting from short falls among young children: less than 1 in 1 million. *Pediatrics*. 2008;121(6):1213–1224
- 32. Mishra P, Naithani R, Dolai T, et al. Intracranial haemorrhage in patients with congenital haemostatic defects. *Haemophilia*. 2008;14(5):952–955
- Nelson MD Jr, Maeder MA, Usner D, et al. Prevalence and incidence of intracranial haemorrhage in a population of

children with haemophilia. The Hemophilia Growth and Development Study. *Haemophilia*. 1999;5(5):306–312

- Hayward CPM, Rao AK, Cattaneo M. Congenital platelet disorders: overview of their mechanisms, diagnostic evaluation and treatment. *Haemophilia*. 2006;12(Suppl 3):128–136
- 35. Nichols WL, Hultin MB, James AH, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171–232
- Shearer MJ. Vitamin K deficiency bleeding (VKDB) in early infancy. *Blood Rev.* 2009;23(2):49–59
- Miyasaka M, Nosaka S, Sakai H, et al. Vitamin K deficiency bleeding with intracranial hemorrhage: focus on secondary form. *Emerg Radiol.* 2007; 14(5):323–329
- Labarque V, Stain AM, Blanchette V, Kahr WH, Carcao MD. Intracranial haemorrhage in von Willebrand disease: a report on six cases. *Haemophilia*. 2013;19(4):602–606
- Talving P, Lustenberger T, Lam L, et al. Coagulopathy after isolated severe traumatic brain injury in children. *J Trauma*. 2011;71(5):1205–1210
- Ragni MV, Bontempo FA, Hassett AC. von Willebrand disease and bleeding in women. *Haemophilia*. 1999;5(5): 313–317
- Ziv O, Ragni MV. Bleeding manifestations in males with von Willebrand disease. *Haemophilia*. 2004;10(2):162–168
- Mizoi K, Onuma T, Mori K. Intracranial hemorrhage secondary to von Willebrand's disease and trauma. *Surg Neurol.* 1984;22(5):495–498
- 43. Nayak K, Spencer N, Shenoy M, Rubithon J, Coad N, Logan S. How useful is the presence of petechiae in distinguishing non-accidental from accidental injury? *Child Abuse Negl.* 2006;30(5):549–555